The use of Mendelian randomization (MR) provides a way to assess whether the production of uromodulin, reflected by its urinary levels, is a true risk factor for CKD, and whether this potential association is related to blood pressure (Fig. 4). This evidence concerns the gene UMOD and chronic kidney disease.